Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases
and over time causes fibrosis and eventually cirrhosis of the new liver. The aim of this
study was to see if the frequency of liver fibrosis was different with cyclosporine
microemulsion than tacrolimus